Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)
NCT06184360
·
clinicaltrials.gov ↗
COMPLETED
Status
2079
Enrollment
INDUSTRY
Sponsor class
Conditions
Neovascular (Wet) Age-related Macular Degeneration
Sponsor
Novartis Pharmaceuticals